• 1
    Tieman J, Sladek R, Currow D. Changes in the quantity and level of evidence of palliative and hospice care literature: the last century. J Clin Oncol. 2008; 26: 5679-5683.
  • 2
    Hui D, Parsons HA, Damani S, et al. Quantity, design, and scope of the palliative oncology literature. Oncologist. 2011; 16: 694-703.
  • 3
    O'Mara AM, St Germain D, Ferrell B, Bornemann T. Challenges to and lessons learned from conducting palliative care research. J Pain Symptom Manage. 2009; 37: 387-394.
  • 4
    Hui D, Reddy A, Parsons H, Bruera E. Reporting of funding sources and conflict of interest in the supportive and palliative oncology literature. J Pain Symp Manage. 2012; 44: 421-430.
  • 5
    Grande GE, Todd CJ. Why are trials in palliative care so difficult? Palliat Med. 2000; 14: 69-74.
  • 6
    Hui D, Arthur J, Dalal S, Bruera E. Quality of the supportive and palliative oncology literature: a focused analysis on randomized controlled trials. Support Care Cancer. 2012; 20: 1779-1785.
  • 7
    Rinck GC, van den Bos GA, Kleijnen J, de Haes HJ, Schade E, Veenhof CH. Methodologic issues in effectiveness research on palliative cancer care: a systematic review. J Clin Oncol. 1997; 15: 1697-1707.
  • 8
    Jordhoy MS, Kaasa S, Fayers P, Ovreness T, Underland G, Ahlner-Elmqvist M. Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med. 1999; 13: 299-310.
  • 9
    McWhinney IR, Bass MJ, Donner A. Evaluation of a palliative care service: problems and pitfalls. BMJ. 1994; 309: 1340-1342.
  • 10
    Philip J, Smith WB, Craft P, Lickiss N. Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. Support Care Cancer. 1998; 6: 539-541.
  • 11
    Stromgren AS, Groenvold M, Pedersen L, Olsen AK, Sjogren P. Symptomatology of cancer patients in palliative care: content validation of self-assessment questionnaires against medical records. Eur J Cancer. 2002; 38: 788-794.
  • 12
    Moro C, Brunelli C, Miccinesi G, Fallai M, Morino P, Piazza M, et al. Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer. 2006; 14: 30-37.
  • 13
    Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage. 2004; 28: 381-388.
  • 14
    Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004; 22: 185-192.
  • 15
    Bruera E, Sala R, Spruyt O, Palmer JL, Zhang T, Willey J. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005; 29: 613-618.
  • 16
    Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003; 21: 4439-4443.
  • 17
    Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007; 25: 3475-3481.
  • 18
    Bruera E, Sala R, Rico MA, et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol. 2005; 23: 2366-2371.
  • 19
    Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006; 24: 2073-2078.
  • 20
    Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, et al. Dexamethasone (DM) for cancer related fatigue: a double-blinded, randomized, placebo-controlled trial [abstract]. Presented at: 48th American Society of Clinical Oncology Annual Meeting; June 2012, Chicago, IL,
  • 21
    Oldervoll LM, Loge JH, Paltiel H, et al. Are palliative cancer patients willing and able to participate in a physical exercise program? Palliat Support Care. 2005; 3: 281-287.
  • 22
    McMillan SC, Weitzner MA. Methodologic issues in collecting data from debilitated patients with cancer near the end of life. Oncol Nurs Forum. 2003; 30: 123-129.
  • 23
    Karlson CW, Rapoff MA. Attrition in randomized controlled trials for pediatric chronic conditions. J Pediatr Psychol. 2009; 34: 782-793.
  • 24
    Zimmermann C, Riechelmann R, Krzyzanowska M, Rodin G, Tannock I. Effectiveness of specialized palliative care: a systematic review. JAMA. 2008; 299: 1698-1709.
  • 25
    Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol. 2011; 29: 1151-1158.
  • 26
    Applebaum AJ, Lichtenthal WG, Pessin HA, et al. Factors associated with attrition from a randomized controlled trial of meaning-centered group psychotherapy for patients with advanced cancer [published online ahead of print July 12, 2011]. Psychooncology. doi: 10.1002/pon.2013.
  • 27
    Osann K, Wenzel L, Dogan A, et al. Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial. Gynecol Oncol. 2011; 121: 558-564.
  • 28
    Siddiqi AE, Sikorskii A, Given CW, Given B. Early participant attrition from clinical trials: role of trial design and logistics. Clin Trials. 2008; 5: 328-335.
  • 29
    Joseph G, Dohan D. Diversity of participants in clinical trials in an academic medical center: the role of the ‘Good Study Patient?’. Cancer. 2009; 115: 608-615.
  • 30
    Braunstein JB, Sherber NS, Schulman SP, Ding EL, Powe NR. Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials. Medicine (Baltimore). 2008; 87: 1-9.
  • 31
    Corbie-Smith G, Thomas SB, St George DM. Distrust, race, and research. Arch Intern Med. 2002; 162: 2458-2463.
  • 32
    Steinhauser KE, Clipp EC, Hays JC, et al. Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research. Palliat Med. 2006; 20: 745-754.